Nkp30 Receptor Targeted Therapeutics

Abstract

The invention is directed to T cells and other cells that express chimeric NK-p30 receptors (“chimeric NKp30 T cells”), methods of making and using chimeric NKp30 T cells, and methods of using these chimeric NKp30 T cells, isolated populations thereof, and compositions comprising the same. In another aspect, said chimeric NKp30 T cells are further designed to express a functional non-TCR receptor. The disclosure also pertains to methods of making said chimeric NKp30 T cells, and methods of reducing or ameliorating, or preventing or treating, diseases and disorders using said chimeric NKp30 T cells, populations thereof, or compositions comprising the same.


Claims
Download PDF
Document Preview
Document History
  • Publication: Dec 5, 2017
  • Application: Aug 31, 2012
    US US 201214342060 A
  • Priority: Aug 31, 2012
    US US 201214342060 A
  • Priority: Aug 31, 2012
    US US 2012/0053511 W
  • Priority: Aug 31, 2011
    US US 201161529410 P

Download Citation


Sign in to the Lens

Feedback